Source: Pharmacy Times articles
In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.
Read More
Recent Content
- Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
- Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide
- A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients
- Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study
- PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of elranatamab for multiple myeloma, CPX-351 for myeloid leukemia, inotuzumab ozogamicin for lymphoblastic leukemia, capivasertib for breast cancer, and zolbetuximab for gastric cancer in Japan
- T cell characteristics impact response and resistance to T cell-redirecting bispecific antibodies in multiple myeloma
- Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach
- Complex Pathological Femoral Fracture in a Multiple Myeloma Patient Undergoing Intertrochanteric Fixation: A Case Report
- A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing
- Targeting myeloma essential genes using NOT Gated CAR T-cells, a computational approach